

Research Ethics Committee Reference Number	Integrated Research Application System (IRAS) number	Name of Trial	Target number of patients agreed?	Min. number of patients agreed	Max. number of patients agreed	Target date to recruit patients agreed?	Date agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Date that the trial closed to recruitment	Total number of study participants recruited	Reason for closure of trial	Comments
16/EM/0193	190690	A phase III, double-blind, randomized placebo-controlled study to evaluate the effects of dalcetrapib on cardiovascular (CV) risk in a genetically defined population with a recent Acute Coronary Syndrome (ACS): The Dal-GenE trial	Number Agreed	6	6	Date Agreed	30/11/2018	2	15/12/2018	2	Recruitment Finished	High number of screen failures.
15/SW/0089	164916	Entyvio (vedolizumab) long-term safety study: An international observational prospective cohort study comparing vedolizumab to other biologic agents in patients with ulcerative colitis or Crohn's Disease	Number Agreed	20	40	Date Agreed	30/06/2019	17	30/06/2019	17	Recruitment Finished	High number of screen failures.